Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,226 recruiting studies in this area right now.
By phase
- Not applicable9,543
- Phase 24,410
- Phase 12,677
- Phase 1/Phase 21,654
- Phase 31,397
- Phase 2/Phase 3284
- Phase 4261
Top conditions
- Breast Cancer1,200
- Prostate Cancer645
- Cancer635
- Colorectal Cancer480
- Lung Cancer418
- Ovarian Cancer338
- Multiple Myeloma330
- Pancreatic Cancer290
- Gastric Cancer281
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer226
- Cervical Cancer225
- Endometrial Cancer210
- Advanced Solid Tumors203
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University275
- Mayo Clinic238
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences143
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,414
- Texas634
- Arizona507
- Florida437
- Alabama428
- New York406
- Massachusetts342
- Maryland329
- New Jersey273
- Pennsylvania232
Recruiting studies20,226 total
- NCT06069570RecruitingPhase 1
Gamma delta T cells and low dose radiation for advanced lung or bone cancer
This trial tests a new type of immune cell called gamma delta T cells combined with low-dose radiation to treat people with advanced lung cancer or solid tumors that have spread to the bone. It is only for patients who have already tried standard treatments and either didn't get better or couldn't tolerate them.
Tucson, ArizonaAges 18 years+ - NCT06363591Recruiting
One vs two surgeries for thin melanoma
This trial compares having one surgery to remove extra skin around a thin melanoma versus the standard two-step approach (biopsy first, then a wider excision later). It aims to see if one surgery is just as safe and reduces the number of procedures.
GothenburgAges 18 years+ - NCT06443489RecruitingPhase 1
SHR-4849 for advanced solid tumors
This trial tests a new drug called SHR-4849 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have limited choices.
Jilin City, ChangchunAges 18–75 - NCT06643000Recruiting
High-dose furmonertinib combo for EGFR lung cancer with brain lining spread
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Zhengzhou, HenanAges 18 years+ - NCT07341191RecruitingPhase 2
Sonrotoclax and zanubrutinib before CAR-T for mantle cell lymphoma
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
Calgary, AlbertaAges 18 years+ - NCT06859203Recruiting
PET scan study for men with rising PSA after prostate cancer treatment
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT07334431RecruitingPhase 1/Phase 2
A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Zhengzhou, HenanAges 18–75 - NCT07342231Recruiting
FAPi PET scan for pancreatic cancer
This trial uses a special PET scan (FAPi PET) to see if it can help spot pancreatic ductal adenocarcinoma better than standard scans. It may offer a more precise way to check the extent of the disease.
Mumbai, MaharashtraAges 18 years+ - NCT07338968Enrolling by invitation
Long-term follow-up for early choroidal melanoma study
This study follows people who finished a previous trial for a type of eye cancer called early choroidal melanoma. It checks how patients are doing over time after receiving either the study treatment (bel-sar) or a placebo (sham).
Sacramento, CaliforniaAges 18 years+ - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT07336472RecruitingPhase 1/Phase 2
IBI3003 for relapsed or refractory multiple myeloma
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07335003Recruiting
Sunscreen study for preventing skin damage in older adults with actinic keratoses
This study tests a new sunscreen (Anthelos Fluide 100 KA+ UVMune 400) to see if it can protect skin and prevent further sun damage in people who already have multiple actinic keratoses (precancerous spots). It may help reduce the risk of new spots or skin cancer.
Camperdown, New South WalesAges 60 years+ - NCT07334483RecruitingPhase 2
Radiation plus targeted immunotherapy for liver cancer
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
BeijingAges 18–75 - NCT07337525RecruitingPhase 1
First study of PLT012 in advanced solid tumors
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
Los Angeles, CaliforniaAges 18 years+ - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07336823RecruitingEarly Phase 1
JY232 CAR-T cell therapy for relapsed multiple myeloma
This trial tests an investigational CAR-T cell therapy called JY232 for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy targets a protein called BCMA on myeloma cells to help your immune system fight the cancer.
Foshan, GuangdongAges 18–75 - NCT07340190RecruitingPhase 1
How pelabresib affects other drugs in advanced cancer
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
BordeauxAges 18 years+ - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT07337590Recruiting
New device to monitor healing after colorectal cancer surgery
This trial tests a new system that monitors healing inside the body after surgery for colorectal cancer. It is designed to help doctors detect problems early and keep you safe.
Louisville, KentuckyAges 21 years+ - NCT07341464Recruiting
Blended tube feeding for children and adults
This study tests if a blended tube-feeding formula made from real food is easy to tolerate and acceptable for people who already use a gastrostomy tube. It may be a good option if you or your child need extra nutrition through a tube.
NottinghamAges 1 year+ - NCT04460352RecruitingPhase 3
Esophageal cancer treatment with chemoradiation plus planned surgery
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
Montreal, QuebecAges 18–80
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,226 recruiting oncology studies from the U.S. registry right now, out of 30,453 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.